News & Views

Press Releases

Stephanie Psaki Appointed to Lead the Population Council’s Girl Innovation, Research, and Learning (GIRL) Center

NEW YORK, NEW YORK (September 10, 2019) – The Population Council has announced that Stephanie Psaki has become director of the Population Council’s Girl, Innovation, Research, and Learning (GIRL) Center – a collaborative global research hub dedicated to generating, synthesizing and disseminating evidence to transform the lives of the 1.2 billion adolescents worldwide.

Read more

Population Council receives $100,000 gift to seed-fund African biomedical fellowships

Mr. Martin Jeiven, a long-term collaborator of the Population Council’s Center for Biomedical Research (CBR), has pledged $100,000 to seed-fund a new fellowship program for laboratory scientists from Africa. Fellow will spend three months working alongside Population Council scientists in our laboratories at Rockefeller University before returning to their home institution to lead collaborations with CBR.

Read more

Population Council’s Ethiopia “Child Marriage Prevention” Expertise Takes Center Stage

The Population Council has been conducting high-quality research to determine what works and what doesn’t work to empower girls and prevent child marriage for years. That expertise and our research in Ethiopia took center stage in a BBC World Service feature, in a featured piece at Voice of America, and in a blog post featuring Malala Yousafzai and her girls’ education advocacy organization, the Malala Fund.

Read more

Press Releases

Phase 3 Results Show Population Council’s One-Year Contraceptive Vaginal System Highly Effective

Phase 3 Results Show Population Council’s One-Year Contraceptive Vaginal System Highly Effective
Photo credit: Population Council / Hallie Easley

NEW YORK, NEW YORK (June 20, 2019) – The Lancet Global Health today published results from the Phase 3 clinical efficacy trials of the Population Council-developed Annovera™ (segesterone acetate and ethinyl estradiol vaginal contraceptive system).  Annovera is the first and only contraceptive that provides an entire year of protection against unintended pregnancy while fully under a woman’s control.  Results show that Annovera was 97% effective in preventing pregnancy for up to 13 menstrual cycles, which means that women do not need to return to the clinic or pharmacy for prescription refills.

Read more

Media Coverage

The New York Times: Women and Clinical Trials

In response to a New York Times report on the dearth of women enrolled in H.I.V. clinical trials, Ruth Merkatz, director of clinical development at the Population Council’s Center for Biomedical Research and former director of the Office of Women’s Health at the FDA, wrote a letter to the editor about the essential need for gender equality in clinical trials.

Read more

Council Commentary

Examining the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study

Examining the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study
Photo credit: FHI 360

The Population Council welcomes publication of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) study. We congratulate the trial organizers and appreciate the more than 7,800 women in four countries in East and Southern Africa whose participation in the trial advances our understanding of women’s needs and choices in contraception and HIV prevention.

Read more